A number of patients with renal cell carcinoma (RCC) are faced with the knowledge that, despite undergoing nephrectomy, they have a substantial risk of disease recurrence. Prior efforts to decrease recurrence risk using immunotherapy have largely been ineffective. The reasons for the failure of immunotherapy are not clear, as our ability to measure immunological outcomes has not provided us with clues on the determinants which signal a successful antitumor effect.
R enal cell carcinoma affects over 40,000 people per year in the United States and results in close to 13,000 deaths. 1 Patients with nonmetastatic disease are generally treated with nephrectomy and depending on the pathologic stage and grade of the tumor will experience outcomes ranging from a high probability of cure down to near certain relapse. 2, 3 Nearly 50% of all patients with renal cell carcinoma (RCC) will have metastatic disease upfront or at some point in time during their disease course, and adjuvant therapy is clearly needed to improve the fate of high-risk patients. 4 Efforts have been made for several decades to decrease the risk of relapse in high risk RCC. Modalities have included radiation therapy, 5 hormonal therapy, 6 and immunotherapy, [7] [8] [9] [10] [11] [12] and none has yet proven to be consistently effective. More recently, targeted antivascular therapy has been shown to alter the course of disease in the metastatic setting, [13] [14] [15] [16] and efforts are underway to assess the utility of these agents in the adjuvant setting. The ideal agent to test in the adjuvant setting should be effective in treating metastatic disease, easy to administer (oral is preferable over parental administration), and should have a low toxicity profile for chronic use.
The following sections will summarize existing and ongoing trials of adjuvant therapy in RCC, followed by a description of the ongoing research to accelerate discovery and personalize therapy in this disease state.
METHODS

Search Strategy and Selection Criteria
Data for this review were identified by searches of MEDLINE, PubMed, and references from relevant articles using the terms "renal cell carcinoma," and "adjuvant therapy." Abstracts from the 2008 American Society of Clinical Oncology meeting were included. Articles published in English between 1980 and 2008 were included.
RESULTS
Patient Selection for Adjuvant Therapy-Current Risk Stratification Algorithms
A number of algorithms have been developed to predict risk recurrence in patients with RCC (Table 1 ). These include purely clinical algorithms, 17, 18 and algorithms that incorporate postoperative tumor staging and histologic characteristics. 3, 19, 20 The study by Leibovich et al 40 includes histologic tumor necrosis as an additional variable.
These algorithms are helpful in predicting risk of relapse, and use readily available data and techniques to categorize patients. These algorithms do not provide a biologic rationale for patient subcategorization, since no validated molecular marker exists that can be incorporated into the existing schemas. As we gain knowledge about the determinants of relapse in the adjuvant setting, a new generation of algorithms will arise categorizing patients by risk and by mechanism of relapse, permitting the application of tailored therapy.
Adjuvant Therapy with Immunotherapy
Interferon (IFN) alpha therapy was shown in 2 randomized trials to improve survival in patients with metastatic RCC, 21, 22 and high-dose interleukin-2 therapy demonstrated a durable complete response rate of approximately 5%, 23 resulting in its approval by the Food and Drug Administration in 1992. Since immunotherapy is assumed, based on findings in animal models, to work best in the minimal disease state, it was hoped that this modality would work particularly well in the adjuvant setting.
Several randomized trials have subsequently been performed assessing cytokines and vaccines in the adjuvant setting, but none has demonstrated a survival advantage favoring therapy ( Table 2) . Two randomized trials assessing adjuvant IFN failed to show a benefit for the treatment group. 7, 11 The autologous vaccine trial performed by Jocham et al 9 demonstrated an improved progression-free survival (PFS) in the treatment group, but 174 patients were lost to follow up after randomization. A 728 patient trial evaluating vitespen, an autologous heat-shock protein derived vaccine, did not show an overall difference in PFS. 12 A randomized trial assessing biochemotherapy in the adjuvant setting resulted in superior outcome in the observation arm. 24 At present, we do not know why these immunotherapeutic strategies failed to achieve the desired results. The recent discovery of a new class of negative regulatory immune cells, 25 the development of more potent immunoregu-latory molecules, 26 and our improved ability to assay in vivo immunologic events 27 may provide us with the ability to improve adjuvant immunotherapy for RCC.
Rationale for Using Antivascular Agents in the Adjuvant Setting
Targeted antivascular agents have recently changed the treatment landscape in metastatic RCC. With the approval of sorafenib, 14 sunitinib, 13 and temsirolimus 15 and the promising results seen with the combination of bevacizumab and IFN, 16 a much larger range of options now exists for patients with metastatic RCC, with an improvement in PFS, [13] [14] [15] [16] and overall survival 15 seen in these studies.
The development of antivascular agents arose out of an evolving understanding of angiogenesis and factors that drive it. The von Hippel Lindau (VHL) gene was discovered in 1993, 28 and mutational and functional inactivation of the VHL gene is found in sporadic RCC. 29 VHL is responsible for the oxygen dependent regulation of hypoxia-inducible factor 1 and 2 alpha (HIF1a and HIF2a), 30 2 transcription factors that upon heterodimerization to HIF1b drive the expression of a number of proangiogenic factors, including vascular endothelial growth factor (VEGF). 31 Although sunitinib, sorafenib, bevacizumab, and possibly temsirolimus act by inhibiting the VEGF receptor (sorafenib, sunitinib), the VEGF ligand itself (bevacizumab), or via intracellular regulation of HIFa (temsirolimus), it is not certain that these agents will prevent metastates. Although tumor neovascularization is important for growth and its inhibition may stop the progression of micrometastases, it is also apparent that alternate pathways can develop, possibly circumventing VEGF pathway inhibition. 32 If micrometastases are driven to develop these alternate pathways early on, resistant tumors may result. It is therefore important that the correlative studies being performed in conjunction with the ongoing clinical trials address these issues.
Ongoing Trials Using Targeted Agents in the Adjuvant Setting
No mature data currently exist on the efficacy of targeted therapy in the adjuvant setting. To address this challenge, several clinical trials are currently underway ( Table 3 ). The Eastern Cooperative Oncology Group 2805 ASSURE (adjuvant sorafenib or sunitinib in unfavourable RCC) is a double-blinded trial that is randomizing 1332 patients to receive 1 year of sunitinib, sorafenib, or placebo. 33 The primary endpoint is disease-free survival (DFS). Patients are eligible if they have a nephrectomy demonstrating the following findings: pT1b, G3-4; pT2-pT4; or any T-stage with node-positive disease. The study will assess the frequency of oncogene and tumor suppressor gene mutations, tumor and genetic polymorphisms and DNA methylation profiles as predictors of DFS, and therapeutic benefit. It will correlate polymorphisms in drug-metabolizing enzymes with steadystate concentrations of sorafenib or sunitinib in selected patients. Additionally, it will study the effect of VEGFtargeted therapy on circulating endothelial cells and circulating endothelial progenitors. The study opened in May 2006, and at the time of publication, this trial is accruing rapidly. The Sunitinib Treatment of Renal Adjuvant Cancer (S-TRAC) trial is a double-blind phase 3 study randomizing 290 subjects with high risk RCC defined by UISS criteria to receive adjuvant sunitinib given at 50 mg daily on a 4-week on, 2-week off schedule versus placebo on the same schedule for 1 year or until recurrence of RCC or occurrence of a secondary malignancy, significant toxicity, or subject withdrawal of consent. The primary end-point of the study is DFS, and the secondary endpoints are relapse-free survival, overall survival, patient-reported outcomes and safety.
The SORCE trial (a phase 3, randomized, double-blind, controlled study comparing sorafenib with placebo in patients with resected primary RCC at high or intermediate risk of relapse) will randomize patients between placebo, 1 year of sorafenib or 3 years of sorafenib in a 2:3:3 ratio. Patients who progress in arms 1 or 2 will be permitted crossover to sorafenib. The primary endpoint is metastasis-free survival (MFS). To show a clinically important improvement in MFS from 63.5% to 71% (HR ϭ 0.75) with sorafenib requires 608 events for MFS in 1656 patients (414 patients in arm A and 621 in each of arms B and C), using a log-rank test with 90% power and 5% two-sided significance level. 34 Tumor and blood samples will be collected to evaluate predictive biomarkers. 34 The SORCE trial opened in July 2007 and is accruing patients.
Neoadjuvant Therapy
Neoadjuvant therapy is commonly used in other solid tumors, and has shown a survival advantage in bladder cancer. 35 As of recently, there are no published studies describing the use of neoadjuvant therapy in nonmetastatic RCC. There are a number of theoretical advantages to administer presurgical therapy, including tumor downstaging, assessment of primary tumor response, decreasing circulating tumor cells and proangiogenic factors, and potentially im-proving the performance status of patients before nephrectomy. The only manner in which we can determine whether this approach has any merit is by performing appropriately designed clinical trials.
Are Patients Doing Well Because of Treatment, or Despite Treatment-How Do We Deal With Biologic Heterogeneity in Adjuvant Trials?
A key dilemma for any adjuvant therapy strategy is defining the patients who will benefit from treatment. If we think of a hypothetical clinical trial where one half of the patients receive a purported adjuvant therapy in a randomized trial, 3 outcomes are possible for patients on the study group (Fig. 1) . Patients may show an improved outcome because of therapy. A second group may not in any way be impacted by therapy. A third group may be harmed by therapy. If the first and third groups are evenly balanced, we will end up with an outcome that, on the surface states that no difference exists between study and control group, despite the fact that profound biologic differences exist in subsets of patients. Since the biology that underpins the determinants of success and failure may not be obvious, conventional subgroup analyses will not permit us to identify the biologically relevant subgroups.
Our analysis of nephrectomy specimens from patients pretreated with bevacizumab indicates that biologic heterogeneity in key pathways clearly exists. 36 What we do not know is whether this heterogeneity is innate or induced, and ongoing work will answer this question. If these or similar pathways are also biologically relevant in the adjuvant setting, then we may soon have the ability to stratify patients among different therapies according to predetermined criteria. Further observations in the metastatic setting provide a cautionary tale for the development of adjuvant therapy. In a review of 162 patients with metastatic disease, we observed that 18% of patients with metastatic disease on targeted therapy failed in a new site while maintaining tumor control in the existing sites of metastatic disease. 37 These data imply that targeted agents may not possess antimetastatic activity as much as they provide static activity on existing tumor deposits.
Fortunately, the 2 large randomized adjuvant clinical trials currently underway are collecting tissue and blood, and possess a number of correlative endpoints that will undoubtedly shed light on some of the factors that define populations most likely to benefit from adjuvant therapy, and those that fail. 33, 34 We will need to consider the state of the epithelial, stromal, and vascular compartments, as well as define the state of circulating tumor cells ( Fig. 2) .
As an example, an animal model of antivascular therapy resistance is described in a recent article. Here, bonemarrow derived monocytic cells contribute to anti-VEGF therapy resistance, which can be overcome by blocking signaling via alternate angiogenic pathways. 38 It is possible a similar process is operative in the adjuvant setting as well.
Proposed Clinical Trial Design to Test Correlative Hypotheses
As the correlative data from the 2 randomized clinical trials become available, the question of how to test the hypotheses in an efficient manner will become important. At our institution, we successfully completed a trial evaluating neoadjuvant versus adjuvant therapy in high-risk bladder cancer. 39 Untreated and treated tissue is available from this study. A similar approach is feasible in patients with highrisk renal cell carcinoma. This approach permits testing whether resistance factors are induced or innate, and if the operating characteristics of the assays are well defined, the study can be appropriately powered to evaluate correlative endpoints.
SUMMARY
Patients with high risk RCCs face a challenging prognosis with no defined treatment options. We now have access to antivascular agents with proven efficacy in the metastatic setting and clinical trials are underway to determine whether these agents are helpful in the adjuvant setting. As these trials accrue, we need to define which patients benefit from therapy and characterize the mechanism of failure in the patients who do not. We need to develop appropriate molecular tools to answer these important questions and move towards personalized medicine in the adjuvant setting.
